Business Context and Reporting Period
This Form 8-K Current Report was filed by Dandrit Biotech USA, Inc. (referred to in metadata as Lunai Bioworks Inc.) on May 1, 2017. The registrant is a Delaware corporation with principal executive offices in Copenhagen, Denmark. The report details the completion of a private placement offering of equity securities.
Key Financial Metrics
The filing reports the following specific financial data related to the capital raise:
- Total Proceeds: $3,510,000
- Shares Issued: 2,700,000 shares of Common Stock
- Warrants Issued: 5,400,000 warrants (2 per unit)
- Offering Price: $1.30 per Unit (1 share + 2 warrants)
- Warrant Strike Price: $1.30 per share
- Post-Issuance Share Count: 12,433,290 shares issued and outstanding
- Dilution: The issuance represented 27.74% of the total Common Stock outstanding immediately prior to the closing.
The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or general liquidity metrics beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock from 9,733,290 shares to 12,433,290 shares following the private placement. The company raised $3,510,000 in gross proceeds, which represents a significant capital injection relative to the pre-offering share count. No underwriters or placement agents were engaged for this transaction.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future business outlook, revenue guidance, or operational risks. The transaction was conducted pursuant to Rule 506 of Regulation D and/or Regulation S of the Securities Act. Investors purchasing under Rule 506 were required to be "accredited investors," while those under Regulation S were required not to be "U.S. persons." The warrants are freely exercisable until the fifth anniversary of the issuance date.
Investor Verification Checklist
- Verify the exact legal name of the registrant (Dandrit Biotech USA, Inc.) versus the metadata name (Lunai Bioworks Inc.) to ensure correct entity tracking.
- Confirm the use of the $3,510,000 in proceeds, as the filing does not specify the intended allocation of funds.
- Review the attached Subscription Agreement (Exhibit 10.1) and Warrant (Exhibit 10.2) for specific terms, vesting schedules, or redemption rights not detailed in the summary.
- Assess the impact of the 27.74% dilution on existing shareholder value.
- Check for subsequent filings regarding the company's operational status or financial health, as this 8-K contains no financial statements.